Отчет об анализе размера, доли и тенденций мирового рынка протезов клапанов сердца – обзор отрасли и прогноз до 2031 года

Анализ рынка протезов клапанов сердца

Рынок протезов сердечных клапанов демонстрирует устойчивый рост, обусловленный растущей распространенностью сердечно-сосудистых заболеваний и достижениями в области кардиохирургии. Протезы сердечных клапанов имеют решающее значение в лечении таких состояний, как стеноз клапана и регургитация, которые могут серьезно ухудшить функцию сердца, если их не лечить. Например, в статье 2021 года, опубликованной Национальной медицинской библиотекой, указано, что в США ежегодно проводится более 180 000 операций по замене сердечных клапанов, что вносит значительный вклад в рост рынка замены сердечных клапанов. Ожидается, что постоянные исследования и разработки в сочетании с повышением осведомленности о здоровье сердечно-сосудистой системы и вариантах лечения будут поддерживать рост рынка.

Размер рынка искусственных клапанов сердца

Объем мирового рынка протезов клапанов сердца в 2023 году оценивался в 6,96 млрд долларов США, а к 2031 году, по прогнозам, он достигнет 14,69 млрд долларов США, при среднегодовом темпе роста 9,79% в прогнозируемый период с 2024 по 2031 год. Помимо информации о рыночных сценариях, таких как рыночная стоимость, темпы роста, сегментация, географический охват и основные игроки, рыночные отчеты, подготовленные Data Bridge Market Research, также включают в себя углубленный экспертный анализ, эпидемиологию пациентов, анализ конвейера, анализ цен и нормативно-правовую базу.

Область отчета и сегментация рынка       

Определение рынка протезов клапанов сердца

Протез сердечного клапана — это синтетическое устройство, хирургически имплантируемое для замены поврежденного или больного естественного сердечного клапана. Он служит для восстановления надлежащего кровотока через сердце, имитируя функцию исходного клапана. Протезы сердечных клапанов бывают двух основных типов: механические и биологические. Протезы сердечных клапанов играют решающую роль в лечении заболеваний сердечных клапанов, восстановлении сердечной функции и улучшении качества жизни пациентов.          

Динамика рынка протезов клапанов сердца

Драйверы

• Рост распространенности сердечно-сосудистых заболеваний    

Растущая распространенность заболеваний клапанов сердца, таких как стеноз клапана и регургитация, является значительным драйвером рынка протезов клапанов сердца. Факторы, способствующие этому росту, включают старение населения мира и распространенность нездорового образа жизни, приводящего к таким состояниям, как гипертония и ожирение. Например, статья Национального центра биотехнологической информации (NCBI) за 2023 год показала, что клапанные заболевания сердца поражают примерно 2% населения США, основываясь на оценках Американской кардиологической ассоциации. По мере прогрессирования этих состояний они часто приводят к ухудшению работы клапанов сердца, что требует хирургического вмешательства. Протезы клапанов сердца играют решающую роль в лечении тяжелых случаев, когда нарушается собственная функция клапана, обеспечивая пациентам улучшение качества жизни и увеличение ее продолжительности. Растущая осведомленность о здоровье сердечно-сосудистой системы и достижения в области диагностических возможностей дополнительно способствуют раннему выявлению и лечению, подпитывая спрос на протезы клапанов сердца во всем мире.            

• Растущее старение населения      

The demographic shift towards an older population globally is boosting demand for prosthetic heart valves. As people age, the risk of developing cardiovascular diseases increases, including degenerative conditions affecting heart valves. This demographic trend translates into a larger pool of patients requiring heart valve replacement surgeries to restore proper cardiac function. Prosthetic heart valves offer effective solutions for elderly patients who may not be suitable candidates for other treatments due to age-related health concerns. Moreover, advancements in medical care and improved life expectancy drive the need for durable and reliable prosthetic heart valve options.

Opportunities

• Development of Transcatheter Heart Valves   

The development of transcatheter heart valve technologies represents a significant advancement in cardiac care, offering less invasive alternatives to traditional surgical valve replacement. These minimally invasive procedures allow for the replacement of diseased heart valves without open-heart surgery, reducing recovery times, complications, and hospital stays. Transcatheter heart valves are particularly beneficial for high-risk patients who may not tolerate traditional surgery well. This technological innovation expands treatment options and improves accessibility to valve replacement therapies for a broader patient population. Continued research and development in transcatheter valve technologies are expected to create new opportunities for market growth and innovation in cardiac surgery.  

• Technological Advancements in Cardiac Surgery    

Technological advancements in cardiac surgery have revolutionized the treatment landscape for heart valve disorders by enhancing surgical techniques and prosthetic valve materials. Minimally invasive approaches, such as transcatheter valve replacement and robotic-assisted surgery, have significantly improved patient outcomes compared to traditional open-heart procedures. These techniques involve smaller incisions, reduced trauma to surrounding tissues, and shorter recovery times, allowing patients to return to normal activities sooner. These innovations not only broaden the eligible patient population by including higher-risk patients who may not tolerate extensive surgery but also enhance overall surgical precision and long-term outcomes, creating new market opportunities.

Restraints/Challenges

• High Cost of Prosthetic Heart Valves     

The high cost associated with prosthetic heart valve procedures, particularly mechanical valves requiring lifelong anticoagulation therapy, presents a significant barrier to adoption, particularly in lower-income regions. The expense not only includes the initial implantation procedure but also ongoing medical management and monitoring. This financial burden limits access to prosthetic heart valve treatments for patients in regions with limited healthcare resources or inadequate insurance coverage, challenging the market growth.      

• Risk of Complications of Surgeries   

Prosthetic heart valve replacement surgeries carry inherent risks of complications such as valve thrombosis, infection, and structural deterioration over time. These potential complications necessitate meticulous patient selection, thorough pre-operative evaluation, and vigilant post-operative care to minimize risks and ensure optimal outcomes. The complexity of managing these risks can deter some patients and healthcare providers from choosing valve replacement surgery as a treatment option.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Prosthetic Heart Valve Market Scope

The market is segmented on the basis of type, product, technology, and end use. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Transcatheter Heart Valve
• Tissue Heart Valve
• Mechanical Heart Valve

Product

• Repair Products
• Mitral Valve Repair Devices
• Tricuspid Valve Repair Devices

Technology

• Biological Valve
• Decellularized Valve

End Use

• Hospitals
• Ambulatory Surgical Centres
• Specialty Clinics
• Others

Prosthetic Heart Valve Market Regional Analysis

The market is analyzed and market size insights and trends are provided by country, type, product, technology, and end use as referenced above.

The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.

North America is expected to dominate the market due to advanced healthcare infrastructure, strong research and development capabilities, and widespread integration of cutting-edge medical technologies within the Prosthetic Heart Valve Market. Leading manufacturers significantly enhance production capacities on a global scale.

Asia-Pacific is expected to witness significant growth during the forecast period due to the introduction of innovative products incorporating technical advancements, increasing demand for minimally invasive devices, and rising incidence of cardiac valve disorders. The expanding populations and economies of countries like India and China are expected to further bolster this growth trajectory.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Prosthetic Heart Valve Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Some of the major players operating in the market are:

• Abbott (U.S.)
• Medtronic (U.S.)
• Boston Scientific Corporation (U.S.)
• Edwards Lifesciences Corporation (U.S.)
• LivaNova PLC (U.K.)
• Cryolife, Inc. (U.S.)
• Lepu Medical Technology (Beijing) Co., Ltd. (China)
• Braile Biomédica (Brazil)
• SYMETIS (Switzerland)
• JenaValve (Germany)
• Colibri Heart Valve (U.S.)
• Cardiac Dimensions Inc. (U.S.)
• Cardiosolutions, Inc. (U.S.)
• Medtentia AB (Sweden)
• MitralSolutions, Inc. (U.S.)
• On-X Life Technologies, Inc. (U.S.)
• Sadra Medical, Inc. (U.S.)
• Sorin S.p.A. (Italy)
• St. Jude Medical, Inc. (U.S.)
• ValveXchange, Inc. (U.S.)

Latest Developments in Prosthetic Heart Valve Market

• In February 2024, Edwards Lifesciences Corporation introduced the EVOQUE tricuspid valve replacement system as the first transcatheter therapy approved by the U.S. Food and Drug Administration (FDA) for treating tricuspid regurgitation (TR). The system is indicated to improve health status in patients with severe symptomatic TR despite optimal medical therapy (OMT), when replacement of the tricuspid valve is considered appropriate by a heart team        
• In March 2023, Abbott announced FDA approval for its Epic Max stented tissue valve to address aortic regurgitation or stenosis. The Epic Max features an optimized design aimed at enhancing blood flow through the valve, further solidifying its efficacy in treating patients with aortic valve disorders   Prosthetic Heart Valve Market Scope

SKU-2125